ArticleJournal of medical biochemistry2026
Biochemical effects of personalized clinical interventions on hepatorenal function, immune response, and inflammatory markers in patients with infections.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatic and renal dysfunction, immune imbalance, and excessive inflammatory activation are common complications in postoperative infections. This study evaluated the biochemical effects of personalized clinical interventions on hepatorenal function, immune responses, and inflammatory cytokines in infected patients. Methods: A total of 110 patients with postoperative infections admitted between January 2023 and January 2025 were randomly assigned to an experimental group or a control group (n = 55 each). The control group received standard clinical care, while the experimental group underwent additional individualized intervention measures. Serum hepatic (AST, ALT) and renal (BUN, SCr, UA) biochemical markers, T-lymphocyte subsets (CD3+, CD4+, CD8+), inflammatory factors (IL-6, CRP TNF-a), and SF-36 quality-of-life scores were assessed before and after intervention. Adverse events were recorded. Results: Post-intervention, AST and ALT levels were significantly lower in the experimental group compared with the control group (P < 0.05). BUN, SCr, and UA were also significantly reduced after individualized intervention (P < 0.05). The experimental group demonstrated higher CD3+ and CD4+ levels and lower CD8+ levels than the control group (P < 0.05). Levels of IL-6, CRP and TNF-a were markedly decreased in the experimental group (P < 0.05). Quality-of-life scores across all domains were significantly higher following individualized intervention (P < 0.05). The incidence of adverse reactions was notably lower in the experimental group (5.45% vs. 20.00%; c2 = 4.010, P = 0.045). Conclusions: Personalized clinical interventions significantly improved hepatic and renal biochemical indices, enhanced immune function, and reduced systemic inflammatory cytokines in patients with postoperative infections. These findings support the integration of individualized strategies into infection management to optimize biochemical and clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.